Zent CS - Search Results

1

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.

VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS. VanDerMeid KR, et al. Among authors: zent cs. Cancer Immunol Res. 2018 Oct;6(10):1150-1160. doi: 10.1158/2326-6066.CIR-18-0319. Epub 2018 Aug 8. Cancer Immunol Res. 2018. PMID: 30089638

2

Update on monoclonal antibody therapy in chronic lymphocytic leukemia.

Zent CS, Kay NE. Zent CS, et al. Clin Adv Hematol Oncol. 2004 Feb;2(2):107-13. Clin Adv Hematol Oncol. 2004. PMID: 16163170 Review.

3

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.

Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Shanafelt TD, et al. Among authors: zent cs. Cancer. 2007 Jun 1;109(11):2291-8. doi: 10.1002/cncr.22662. Cancer. 2007. PMID: 17514743 Free article.

4

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.

Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Zent CS, et al. Leuk Res. 2008 Dec;32(12):1849-56. doi: 10.1016/j.leukres.2008.05.014. Epub 2008 Jun 27. Leuk Res. 2008. PMID: 18584865 Free PMC article. Clinical Trial.

5

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE. Zent CS, et al. Cancer. 2008 Oct 15;113(8):2110-8. doi: 10.1002/cncr.23824. Cancer. 2008. PMID: 18759253 Free PMC article. Clinical Trial.

6

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.

Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE. Zent CS, et al. Cancer. 2010 May 1;116(9):2201-7. doi: 10.1002/cncr.25005. Cancer. 2010. PMID: 20166206 Free PMC article. Clinical Trial.

7

Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.

Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD. Kay NE, et al. Among authors: zent cs. Cancer. 2010 May 1;116(9):2180-7. doi: 10.1002/cncr.25028. Cancer. 2010. PMID: 20187101 Free PMC article. Clinical Trial.

8

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.

Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS. Baig NA, et al. Among authors: zent cs. Leuk Lymphoma. 2012 Nov;53(11):2218-27. doi: 10.3109/10428194.2012.681657. Epub 2012 May 21. Leuk Lymphoma. 2012. PMID: 22475085 Free PMC article.

9

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS. Shanafelt T, et al. Among authors: zent cs. Cancer. 2013 Nov 1;119(21):3788-96. doi: 10.1002/cncr.28292. Epub 2013 Aug 6. Cancer. 2013. PMID: 23922059 Free PMC article. Clinical Trial.

10

The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management.

Barr PM, Zent CS. Barr PM, et al. Among authors: zent cs. Leuk Lymphoma. 2014 Jun;55(6):1219-20. doi: 10.3109/10428194.2013.844343. Epub 2013 Nov 1. Leuk Lymphoma. 2014. PMID: 24047480 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

174 results

Search Page